Biotech investing @a16zbiohealth | prev @UCSF Biophysics, @5AMVentures, @Abbvie, Stemcentrx, GNE
San Francisco, CA
Joined July 2019
- Tweets46
- Following286
- Followers495
- Likes808
Bryan Faust, PhD retweeted
it's awesome to see what hyper low-cost solar from Planted unlocks
turns out, if you can make solar systems radically cheap enough, people like @CJHandmer will use them to make natural gas from sunlight and air.
Bryan Faust, PhD retweeted
We will take all space rocket imagery in biotech land
… especially when we’re working on drugging novel tumor-specific epitopes to treat really difficult cancers
A big congrats on the company launch and $100m series A financing to @a16z portfolio company @stipplebio!
fiercebiotech.com/biotech/bu…
Bryan Faust, PhD retweeted
Big news! I’m joining @AsteraInstitute as CEO of Radial, their new life sciences division.
How we fund, do, and build upon science has long needed an update. At Radial, we design, fund, and operate programs that tackle foundational scientific problems while simultaneously testing better ways to do science.
Bryan Faust, PhD retweeted
Why we’re excited about ADCs with dual payloads and novel payloads! And RLTs against ADC-validated targets.
Hit the same tumor targets, but with different cell killing MoAs or combination payloads.
This is “Chemo 2.0”
Wonderful study. Large part of the resistance to T-DXd derives from PAYLOAD resistance, via SLFN11 loss or efflux pump amplification. Thus, sequencing 2 ADCs with similar payload can lead to cross resistance, while switching payload is more likely to work. jto.org/article/S1556-0864(2…
Bryan Faust, PhD retweeted
Announcing our newest @a16zBioHealth fund: $700M to back the best founders working to make better medicines and to make the practice of medicine better.
To cure disease, to care for our sick, to fix what’s broken is deeply ingrained; it is medicine’s highest aim.
“At @a16z, we believe that the best thing that a society can do for a person is to give them a chance. Give them a shot at a great life…” - @bhorowitz
@vintweeta @julesyoo @BenPortney @Bryan__Faust @zakdoric @JayRughani @daisydwolf @janerheetweets Michael Cialone, Eva Steinman
At Andreessen Horowitz, we just raised over $15B.
With these new funds including American Dynamism ($1.176B), Apps ($1.7B), Bio + Health ($700M), Infrastructure ($1.7B), Growth ($6.75B), and other venture strategies ($3B), we raised over 18% of all venture capital dollars allocated in the United States in 2025.
Why did we raise the money and how do we plan to invest it?
Read more from Ben Horowitz: a16z.news/p/we-raised-15b-wh…
Bryan Faust, PhD retweeted
Automation isn't coming to construction. it's here. Awesome work by the Planted team
Bryan Faust, PhD retweeted
a few months ago we @_DimensionCap quietly funded a team of 3 MIT computer scientists & mathematicians at the forefront of ML & physics+simulation for enzyme design. these. guys. are. cracked
today they're stealthily building the early team. if you're world class, look below 👇
Bryan Faust, PhD retweeted
It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis or other (non-LCH) histiocytic sarcomas cases.
I'm trying to understand non-surgical chemo and targeted therapy options, new pathology markers to better diagnose subtypes/treatments, and any data on progression in pediatric patients. Please feel free to share – I’m trying to cast a wide net due to the rarity of this condition and how little is known.
People can contact me directly at my first name (as written in my profile) at octant.bio.
Bryan Faust, PhD retweeted
Our goals: New medicines. New practice of medicine.
Our team: @a16z's global venture capital platform, together with @EliLillyandCo, the largest pharma company in the world.
Go :)
Excited about the opportunities ahead! cc @JorgeCondeBio @a16zBioHealth
statnews.com/2025/01/10/eli-…
Bryan Faust, PhD retweeted
How do cells communicate? UCSF's @AashishManglik explored cellular communication through specialized protein receptors at the 29th annual Byers Award Lecture. @ucsfpharmacy tiny.ucsf.edu/MAnu3P
Bryan Faust, PhD retweeted
I'm thrilled to announce the Wankowicz Lab will be opening in August @VanderbiltMPB, AI Center for Protein Dynamics, and @VanderbiltCSB. We will be developing novel methods to model conformational ensembles and study how entropy affects enzyme specificity and catalysis!
Bryan Faust, PhD retweeted
Excited to see the synergistic capabilities of @CartographyBio & @GileadSciences come together to create novel medicines for oncology patients. Way to go @krparker, @ChesterWong, Dan Rock and the rest of the Cartography team!
We're thrilled to announce our strategic collaboration with @GileadSciences to discover and develop therapies for patients with triple-negative #breastcancer and the most common form of non-small cell #lungcancer, adenocarcinoma. Learn more: businesswire.com/news/home/2…
Bryan Faust, PhD retweeted
Great debate between @vijaypande @DaphneKoller and Derek Lowe on the opportunities and challenges for AI in drug development at the #STATBreakthrough summit west
Bryan Faust, PhD retweeted
What's next for Dr. @AashishManglik, winner of the 2024 Bowes Biomedical Investigator award? The cell signaling expert says he's excited to explore new territory: "UCSF is a wonderful place to set up your own shop & get both support & meaningful critique." ucsfh.org/3SLjskv
The biotech industry is built on one of the cleanest go-to-market strategies in existence: if you make a safe drug that really works, patients are likely to receive it and payors are likely to pay for it. Easy, right?
The complexity of biology notwithstanding, how can biotech teams convince prospective investors + partners they've thoughtfully minimized (or at least have mapped out) the risks inherent to drug discovery/development?
In this recent piece, @beckypferdehirt, @vintweeta and I synthesize our thoughts on a key node enabling the biotech financing (and in turn, medicine-creating) lifecycle -- the virtual data room.
a16z.com/virtual-data-rooms-…
As AI masters the language of biology, the ways we interpret science, craft hypotheses, design cures, and fuel the broader bio-economy are poised for radical improvement. The recent explosion of models across the drug discovery lifecycle promises to usher in a new era of medicine.
Today, my @a16zbiohealth colleagues, @vijaypande, @beckypferdehirt, @zakdoric, and I published some of the most pressing “Jobs to be done” for AI in the life sciences.
Get the full insights here: a16z.com/ai-jobs-to-be-done-…
Bryan Faust, PhD retweeted
Our continued interrogation of how odorant receptors decipher a huge diversity of odorants. Started with a cold email to Hiro Matsunami, which led to a brilliant collaboration with @Sci_CadM, @VaidehiLab, @LleBillesb, Ning Ma and others. biorxiv.org/content/10.1101/…
RT @a16zBioHealth: The first drug that crosses the regulatory finish line often becomes the standard of care, securing a dominant market sh…
Bryan Faust, PhD retweeted
I am excited to join @a16z's @a16zBioHealth team as a Venture Partner to work with their investment team and portfolio companies, advising on AI and its enormous potential to advance science and human health. Looking forward to interacting with the vibrant startup ecosystem here!
We're excited to welcome @SuryaGanguli as our newest Bio + Health Venture Partner! A pioneering leader in AI & neuroscience, Surya brings invaluable expertise in leveraging tech to advance healthcare. Read more from @vijaypande here: a16z.com/surya-ganguli-bio-h…
Bryan Faust, PhD retweeted
.🧬🚀 @vintweeta and I couldn't be more excited to have the opportunity to support Mana Bio as they pioneer the field of AI designed LNPs for next generation delivery of genetic medicines. Huge congrats to Mana co-founders @yogevdebbi, @AviSchroeder, @KiraRadinsky and @roynevo !!
Congrats to Mana Bio & co-founder Yogev Debbi on completing their oversubscribed seed round! Mana Bio is pioneering an approach integrating ML into cycles of design, build, test & learn to engineer customized LNPs accelerating genetic therapies.
endpts.com/exclusive-andrees…